Table 5. Reported drug industry funding of patient organisations in Sweden across condition and disease areas (2014–18).
| Condition and Disease area | ICD-10 code | Payment, € (%) | n (%) | Supporting companies | Main donor,€ (%) |
|---|---|---|---|---|---|
| Neoplasms | C00-D49 | 2 419 186 (37.5)1 | 606 (45.3)2 | 22 | Pfizer, 619 662 (25.6)3 |
| Breast | C50 | 663 774 (27.4)3 | 62 (10.2)4 | 5 | Pfizer, 492 074 (74.1)5 |
| Lymphoid, hematopoietic and related tissue | C81-C96 | 463 378 (19.2) | 121 (20.0) | 10 | Celgene, 121 363 (26.2) |
| General | C00-D49 | 416 250 (17.2) | 122 (20.1) | 16 | Roche, 52 592 (12.6) |
| Male genital organs (all prostate) | C61 | 338 684 (14.0) | 134 (22.1) | 8 | Astellas, 148 674 (43.9) |
| Respiratory and intrathoracic organs (all lung) | C30-C39 | 153 225 (6.3) | 50 (8.3) | 11 | Roche, 43 012 (28.1) |
| Digestive organs | C15-C26 | 129 852 (5.4) | 46 (7.6) | 7 | Roche, 60 015 (46.2) |
| Neuroendocrine | C7A | 86 227 (3.6) | 35 (5.8) | 3 | Novartis, 31 075 (36.0) |
| Of uncertain behavior, polycythemia vera and myelodysplastic syndromes | D37-D48 | 81 847 (3.4) | 8 (1.3) | 2 | Novartis, 70 718 (86.4) |
| Female genital organs | C51-C58 | 46 487 (1.9) | 15 (2.5) | 4 | Roche, 19 604 (42.2) |
| Urinary tract | C64-C65 | 19 122 (0.8) | 7 (1.2) | 4 | Pfizer, 8 705 (45.5) |
| Eye, brain and other parts of central nervous system | C71 | 19 165 (0.8) | 4 (0.7) | 1 | Roche, 19 165 (100) |
| Skin | C49 | 1 523 (0.1) | 2 (0.3) | 2 | Eli Lilly, 975 (64.0) |
| Certain infectious and parasitic | A00-B99 | 590 026 (9.1) | 105 (7.9) | 9 | GSK, 360 702 (62.1) |
| HIV | B20-B24 | 469 074 (79.5) | 60 (57.1) | 5 | GSK, 360 702 (76.9) |
| Hepatitis C | B18.2 | 109 481 (18.6) | 39 (37.1) | 4 | AbbVie, 96 526 (95.4) |
| Both HIV and Hepatitis C | B18.2, B20 | 8 391 (1.4) | 4 (3.8) | 1 | AbbVie, 8 391 (100) |
| Other | A84.1 | 3 080 (0.5) | 2 (1.9) | 1 | Pfizer, 3 080 (100) |
| Endocrine, nutritional and metabolic | E00-E90 | 587 605 (9.1) | 121 (9.0) | 14 | Sanofi, 240 600 (40.9) |
| Diabetes (Type 1 or 2) | E10, E11 | 340 972 (58.0) | 79 (65.3) | 9 | Boehringer Ingelheim, 86 889 (25.5) |
| Familial hypercholesterolemia | E78.0 | 162 742 (27.7) | 6 (5.0) | 2 | Sanofi, 157 701 (96.9) |
| Other | E20.9; E27.1; E34.3; E66; E75.22; E76; E85.1; E88.01 | 65 318 (11.1) | 24 (19.8) | 6 | Shire, 24 255 (37.1) |
| Fabry Disease | E75.21 | 18 086 (3.1) | 11 (9.1) | 2 | Shire, 9 125 (50.4) |
| Musculoskeletal system and connective tissue | M00-99 | 446 718 (6.9) | 78 (5.8) | 13 | 124 141 (27.8) AbbVie |
| Rheumatisms (various forms) | M05-06; M08 | 319 150 (71.4) | 45 (57.7) | 11 | AbbVie, 124 141 (38.9) |
| Osteoporosis | M80-M81 | 115 151 (25.8) | 27 (34.6) | 3 | Amgen, 99 854 (86.8) |
| Other | M32; M45 | 12 417 (2.8) | 6 (7.7) | 2 | Novartis, 6 575 (52.9) |
| Digestive system | K00-K95 | 441 717 (6.8) | 53 (4.0) | 11 | AbbVie, 141 150 (32.0) |
| Noninfective enteritis and colitis including Crohn’s | K50-52 | 302 435 (68.5) | 25 (47.2) | 5 | AbbVie, 138 017 (61.2) |
| Other | K00-95; K59; K90 | 139 282 (31.5) | 28 (52.8) | 9 | Takeda, 82 972 (59.6) |
| Nervous system | G00-99 | 437 788 (6.8) | 83 (6.2) | 17 | Biogen, 126 091 (28.9) |
| Other | G10-G99, G12; G24; G40; G44 | 186 102 (42.5) | 34 (41.0) | 12 | Novartis, 40 241 (21.6) |
| Multiple Sclerosis | G35 | 143 060 (32.7) | 23 (27.7) | 6 | Biogen, 106 122 (74.2) |
| Parkinson’s, Alzheimer’s | G20; G30 | 108 626 (24.8) | 26 (31.3) | 8 | AbbVie, 77 334 (71.2) |
| Blood and blood-forming organs and certain disorders involving the immune mechanism | D50-89 | 397 759 (6.2) | 81 (6.1) | 11 | CSL Behring, 115 213 (29.0) |
| Haemophilia | D65-D69 | 321 133 (80.7) | 64 (79.0) | 11 | Bayer, 90 404 (28.2) |
| Immunodeficiency | D84 | 50 800 (12.8) | 12 (14.8) | 4 | CSL Behring, 42 966 (84.6) |
| Other | D56; 61; 84.1 | 25 826 (6.5) | 5 (6.2) | 4 | Novartis, 22 865 (88.5) |
| Circulatory system | I00-99 | 297 491 (4.6) | 50 (3.7) | 10 | Pfizer, 94 870 (31.9) |
| General | I10-I99; I48; I26-I52 | 187 310 (63.0) | 23 (46.0) | 8 | Pfizer, 81 825 (43.7) |
| Atrial fibrillation | I48 | 55 387 (18.6) | 10 (20.0) | 5 | Boehringer Ingelheim, 36 584 (66.1) |
| Cerebral infarction/Stroke | I63 | 30 789 (10.3) | 4 (8.0) | 1 | Bayer, 30 789 (100) |
| Others | I27; I81-I82; I89 | 26 884 (9.0) | 14 (28.0) | 4 | Actelion, 9 924 (36.9) |
| Skin and subcutaneous tissue | L00-L99 | 245 964 (3.8) | 36 (2.7) | 9 | AbbVie, 129 599 (52.7) |
| Psoriasis | L40; L40.50 | 219 709 (89.3) | 32 (88.9) | 8 | AbbVie, 103 626 (47.2) |
| Other | L20; L73.2 | 26 255 (10.7) | 4 (11.1) | 2 | AbbVie, 25 973 (98.9) |
| Various | N/A | 200 863 (3.1) | 36 (2.7) | 14 | Pfizer, 55 326 (27.5) |
| Women’s health | N/A | 108 758 (54.1) | 16 (44.4) | 5 | Pfizer, 55 326 (50.9) |
| Other | N/A | 92 105 (45.9) | 20 (55.6) | 11 | Sanofi, 33 842 (36.7) |
| Respiratory system | J00-J99 | 180 235 (2.8) | 37 (2.8) | 8 | Pfizer, 52 060 (28.9) |
| COPD | J40-J44 | 148 958 (82.6) | 27 (73.0) | 6 | Pfizer, 52 060 (34.9) |
| Asthma | J45 | 17 985 (10.0) | 4 (10.8) | 2 | GlaxoSmithKline, 16 802 (93.4) |
| Lung fibrosis | J84.1 | 13 292 (7.4) | 6 (16.2) | 2 | Roche, 7 947 (59.8) |
| Certain conditions originating in the perinatal period | P00-P96 | 67 177 (1.0) | 16 (1.2) | 3 | AbbVie, 62 844 (93.5) |
| Preterm newborn | P07 | 67 177 (100) | 16 (100) | 3 | AbbVie, 62 844 (93.5) |
| Congenital malformations, deformations and chromosomal abnormalities | Q00-Q99 | 55 330 (0.9) | 15 (1.1) | 4 | Novartis, 39 454 (71.3) |
| Tuberous sclerosis | Q85.1 | 39 454 (71.3) | 9 (60.0) | 1 | Novartis, 39 454 (100) |
| Other | Q61, Q87.1, Q96 | 15 876 (28.7) | 6 (40.0) | 3 | Otsuka, 11 404 (71.8) |
| Mental, Behavioural and Neurodevelopmental | F01-F99 | 42 911 (0.7) | 13 (1.0) | 6 | Janssen, 17 192 (40.1) |
| Schizophrenia | F20 | 29 250 (68.2) | 7 (53.8) | 4 | Janssen, 15 117 (51.7) |
| ADHD | F90 | 10 373 (24.2) | 5 (38.5) | 4 | Novartis, 5 716 (55.1) |
| Other | F11.10 | 3 288 (7.7) | 1 (7.7) | 1 | Shire, 3 288 (0.1) |
| Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | R00-99 | 20 176 (0.3) | 4 (0.3) | 2 | Astellas, 14 884 (73.8) |
| Various | R32; R61 | 20 176 (100) | 4 (100) | 2 | Astellas, 14 884 (73.8) |
| Eye and adnexa | H00-H59 | 10 959 (0.2) | 1 (0.1 | 1 | Santen, 10 959 (100) |
| Glaucoma | H40 | 10 959 (100) | 1 (100) | 1 | Santen, 10 959 (100) |
| Genitourinary system | N00-99 | 7 319 (0.1) | 4 (0.3) | 4 | Otsuka, 2 879 (39.3) |
| Various kidney | N25.81 | 7 319 (100) | 4 (100) | 4 | Otsuka, 2 879 (39.3) |
1 Percent of total value of payments (€6,449,224)
2 Percent of total number of payments (1,337)
3 Percent of total value of payments to condition area
4 Percent of total number of payments to condition area
5 Percent of total value of payments to disease area